ISSN: 1859 - 2872
Antiphospholipid syndrome
Main Article Content
Keywords
Antiphospholipid, anti β2 glycoprotein, lupus anticoagulant
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetric morbidities with persistently positive levels of antiphospholipid antibodies measured on 2 different occasions 12 weeks apart (including anti cardiolipin, anti β2 glycoprotein và lupus anticoagulant). Patients with APS are at increased risk for accelerated atherosclerosis, myocardial infarction, stroke, and valvular heart disease. Approximately 1% of people with APS can have catastrophic APS (CAPS), which is a serious complication of the antiphospholipid syndrome and has a very high mortality rate.
Article Details
References
1. Saigal R, Kansal A, Mittal M et al (2010) Antiphospholipid antibody syndrome. 58: 10.
2. Miyakis S, Lockshin MD (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 4-295.
3. Romisch J, Schorlemmer U (1990) Anticoagulant properties of placenta protein 4 (Annexin V). Thromb Res: 60-355.
4. Chaturvedi S, Braunstein EM, Yuan X et al (2020) Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135(4): 239-251.
5. Radin M, Foddai SG, Cecchi I et al (2020) Antiphosphatidylserine/prothrombin antibodies: An update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 120(4): 592-598.
6. Erkan D, Lockshin MD (2004) What is antiphospholipid syndrome?. Curr Rheumatol Rep 6(6): 451-457.
7. Asherson RA, Cervera R, Piette JC, Shoenfeld Y (2002) The antiphospholipid syndrome II.
8. Aguiar CL, Erkan D (2013) Catastrophic antiphospholipid syndrome: How to diagnose a rare but highly fatal disease. Therapeutic Advances in Musculoskeletal 5(6): 305-314.
9. Pons-Estel GJ, Andreoli L, Scanzi F et al (2017) The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity 76: 10-20.
10. Kello N, Khoury LE, Marder G et al (2019) Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Seminars in Arthritis and Rheumatism 49(1): 74-83.
2. Miyakis S, Lockshin MD (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 4-295.
3. Romisch J, Schorlemmer U (1990) Anticoagulant properties of placenta protein 4 (Annexin V). Thromb Res: 60-355.
4. Chaturvedi S, Braunstein EM, Yuan X et al (2020) Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135(4): 239-251.
5. Radin M, Foddai SG, Cecchi I et al (2020) Antiphosphatidylserine/prothrombin antibodies: An update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 120(4): 592-598.
6. Erkan D, Lockshin MD (2004) What is antiphospholipid syndrome?. Curr Rheumatol Rep 6(6): 451-457.
7. Asherson RA, Cervera R, Piette JC, Shoenfeld Y (2002) The antiphospholipid syndrome II.
8. Aguiar CL, Erkan D (2013) Catastrophic antiphospholipid syndrome: How to diagnose a rare but highly fatal disease. Therapeutic Advances in Musculoskeletal 5(6): 305-314.
9. Pons-Estel GJ, Andreoli L, Scanzi F et al (2017) The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity 76: 10-20.
10. Kello N, Khoury LE, Marder G et al (2019) Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Seminars in Arthritis and Rheumatism 49(1): 74-83.
Article Sidebar
Published
Apr 1, 2021
Section
Articles
How to Cite
LanN. T. T., LongL. H., HàN. L., & LâmH. T. (2021). Antiphospholipid syndrome. Tạp Chí Y Dược lâm sàng 108, 16(DB4). https://doi.org/10.52389/ydls.v16iDB4.937